Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT02879578
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
155
Enrollment
INDUSTRY
Sponsor class
Conditions
Tourette Syndrome
Interventions
DRUG:
Valbenazine
Sponsor
Neurocrine Biosciences